Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

MSI Analysis System, Version 1.2, Technical Manual

Instructions for Use of Product(s)
MD1641

Literature # TM255

The MSI Analysis System, Version 1.2, is a fluorescent PCR-based assay for detection of microsatellite instability. Typically, MSI analysis involves comparing allelic profiles of microsatellite markers generated by amplification of DNA from matching normal and test samples, which may be MMR deficient. Alleles that are present in the test sample but not found in the corresponding normal samples indicate MSI. The MSI Analysis System includes fluorescently labeled primers for co-amplification of seven markers including five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) and two pentanucleotide repeat markers (Penta C and Penta D). The mononucleotide markers are used for MSI determination, and the pentanucleotide markers are used to detect potential sample mixups and/or contamination. Internal lane size standards are added to the PCR samples to assure accurate sizing of alleles and to adjust for run-to-run variation. The PCR products are separated by capillary electrophoresis using an ABI PRISM® 310, 3100 or 3100-Avant Genetic Analyzer or Applied Biosystems 3130 or 3130xl Genetic Analyzer. The output data maybe analyzed with GeneMapper® Analysis Software to determine MSI status.

Summary of Changes
The following changes were made to the 12/20 version of this document:
1. Corrected the URL for the MSI panels and bins text files.
2. Updated formatting for Sections 6.C, 7.C and 8.
3. Updated patent statement.

Revised 12/20.